Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers
Status:
Not yet recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, open-label, 2-arm, multicenter, international study designed to evaluate
the efficacy of zenocutuzumab alone or in combination in patients with the following
diagnoses:
Group A: NRG1+ NSCLC Group B: mCRPC